Log in to search using one of your social media accounts:

 

Can New Indication Give Medtronic Edge in DCB?
Medtronic is entering  a bold new chapter in the continued evolution of its drug-coated balloon technology (DCB). The Dublin-based firm said on Monday, that it received a nod from FDA for the IN.PACT Admiral DCB to treat long superficial femoral artery (SFA) lesions up to 360mm in patients suffering from peripheral artery disease (PAD).  Approval was based on clinical data from the complex lesion imaging cohorts of the IN.PACT Global Study, including long lesion, in-stent restenosis, and chronic total occlusion groups with lesion lengths greater than 180mm. Across these groups, a total of 227 subjects with mean l...
Source: MDDI - April 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

Surmodics Announces FDA Clearance of a New .018” Low-Profile PTA Balloon Dilation Catheter
Company received FDA 510(k) clearance Continued progress in R&D whole-product solutions pipeline EDEN PRAIRIE, Minn. -- (Healthcare Sales & Marketing Network) -- Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologi... Devices, Interventional, FDA Surmodics, percutaneous transluminal angioplasty, balloon catheter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 23, 2018 Category: Pharmaceuticals Source Type: news

Are angioplasty waiting time inequalities growing again?
This research looked at trends between 2002 and 2015 in waiting times for coronary angioplasty. Early indications suggest that socioeconomic inequality in waiting times for non-emergency coronary angioplasty within hospitals may have started rising in England since 2008. It also indicates that waiting times are 20% longer for patients living in deprived areas compared to patient from more affluent neighbourhoods. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 19, 2018 Category: Consumer Health News Source Type: news

Intact Vascular raises $20m in Series C
Intact Vascular said today it raised $20 million in a Series C round of financing, with funds slated to support the company’s Tack endovascular system through the FDA pre-market approval process. The round was joined by major participants New Enterprise Associates, H.I.G. BioVentures and Quaker Partners, the Wayne, Penn.-based company said. The funding is slated to come in two stages or tranches, with the second closing later this year. Late last week, the company posted an SEC filing showing that it had raised $10 million in a round of mixed financing, and that it was seeking an additional $11.8 million before closi...
Source: Mass Device - April 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Vascular Wall Street Beat Intact Vascular Source Type: news

Medical device company Intact Vascular raises $20M
The funds will support the company's development of an implant used in post-angioplasty dissections above the knee. Investors included Philadelphia-based Quaker Partners. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 16, 2018 Category: American Health Authors: John George Source Type: news

Intact Vascular raises $10m, looks to raise $12m more
Intact Vascular has raised $10 million in a new mixed round of financing, according to an SEC filing posted this week. Money in the round comes from 3 anonymous investors, with the first sale noted on April 5, according to the filing. The company has not yet officially stated how it plans to spend the funds, but noted that $2.1 million of the proceeds will be used to pay its executive officers, directors or promoters. Intact Vascular is looking for an additional $11.8 million in the round to close out at $21.8 million, according to the filing. Last July, Intact Vascular announced the European launch of the Toba II BTK clin...
Source: Mass Device - April 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat Intact Vascular Source Type: news

Heavy US Burden of 30-Day Readmissions After PCI Heavy US Burden of 30-Day Readmissions After PCI
Almost 1 in 10 Americans undergoing percutaneous coronary intervention return with an unplanned readmission within 30 days, despite advances in the technology.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Asahi Intecc to begin direct sales of PCTA guidewires
Asahi Intecc said today it plans to begin direct sales of its coronary percutaneous transluminal coronary angioplasty guidewires in the US, which are currently only distributed by Abbott‘s  (NYSE:ABT) vascular division. The shift will take place on July 1, at which time Asahi’s entire portfolio of PTCA guidewires will be available directly from it, the Tustin, Calif.-based company said. All sales requests before the shift will be directed through Abbott, the company said. Asahi said that in preparation for the direct offering, it has increased its sales, clinical, marketing and customer support teams. Repr...
Source: Mass Device - April 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Catheters Distribution Vascular Abbott Asahi Intecc Source Type: news

Abbot launches study comparing OCT to angiography in stent placement procedures
Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography. The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said. “Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT ...
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news

Abbott launches study comparing OCT to angiography in stent placement procedures
Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography. The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said. “Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT ...
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news

Better PCI Outcomes With Genotype-guided Antiplatelet Therapy Better PCI Outcomes With Genotype-guided Antiplatelet Therapy
The use of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI) is associated with better clinical outcomes, according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Abiomed Earns FDA Approval for Adding Optical Sensor to Impella CP Heart Pump
Abiomed, which had a busy 2017 and was among our Company of the Year finalists, reported today that it has received FDA premarket approval (PMA) for its Impella CP heart pump with SmartAssist, utilizing an optical sensor. The sensor is one component of the SmartAssist technology, which also includes a software update enabling informational displays of left ventricular pressure (LVP), end-diastolic pressure (EDP), and cardiac power output (CPO) data on the Impella Console, an Abiomed spokesperson told MD+DI. The Impella CP heart pump had already earned FDA approval for treating patients in cardiogenic shock as well as patie...
Source: MDDI - April 2, 2018 Category: Medical Devices Authors: Daphne Allen Tags: Cardiovascular Source Type: news

Foxtrot ™ NC PTCA Gains Regulatory Approval in Malaysia
(Source: Microport News Release)
Source: Microport News Release - March 29, 2018 Category: Medical Devices Source Type: news

Intact Vascular Has a Unique Way to Treat PAD Patients
Intact Vascular is hoping to have a below-the-knee (BTK) indication for its Tack Endovascular System in 2020 company executives, told MD+DI. Data from the Tack Optimized Balloon Angioplasty Below the Knee (TOBA BTK) clinical trial, an initial study of the technology, was published in the current issue of Catheterization and Cardiovascular Intervention. The published data could help pave the way for an approval.  The Tack Endovascular System is an implant for the precision dissection repair following balloon angioplasty and received CE mark in 2012. The device is designed to help maintain vessel integrity and impr...
Source: MDDI - March 27, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Contego Medical launches Neuroguard IEP trial
Contego Medical said today it launched the Performance I trial of its Neuroguard IEP 3-in-1 carotid stent and post-dilation balloon system with integrated embolic protection designed to treat carotid artery stenosis. The first patient in the trial has already been enrolled and treated at Skopje, Macedonia’s University Clinic of Cardiology by Dr. Saško Kedev, the Raleigh, N.C.-based company said. “We are pleased to initiate this trial evaluating the Neuroguard IEP System, the first of its kind for carotid stenting. Protection from stroke is key during carotid artery interventions. This 3-in-1 system inclu...
Source: Mass Device - March 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Contego Medical Source Type: news

Backlash Over Nixing of CMS Add-On Payments for DCBs
(MedPage Today) -- Superiority of drug-coated balloon angioplasty not reflected in reimbursement, group suggests (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 5, 2018 Category: American Health Source Type: news

FDA clears robotic movement software from Corindus
The FDA granted 510(k) clearance to the first automated robotic movement software designed for Corindus Vascular Robotics (OTC:CVRS) CorPath GRX percutaneous coronary intervention platform, the company reported today. The Rotate on Retract feature allows the person operating the CorPath GRX to navigate to a targeted lesion by automatically turning the guidewire upon joystick retraction. The software also won CE Mark approval in the European Union earlier this year. Today, Dr. Nelson Bernado, the medical director of MedStar Heart Institute’s Peripheral Vascular Laboratory, is slated to perform a robotic-assited p...
Source: Mass Device - March 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Regulatory/Compliance Robotics Software / IT Vascular Corindus Vascular Robotics Source Type: news

ACC, Saudi Arabian Cardiac Interventional Society partner on registries
(American College of Cardiology) The American College of Cardiology and the Saudi Arabian Cardiac Interventional Society have partnered to implement the National Cardiovascular Data Registry's (NCDR) CathPCI Registry in hospitals across Saudi Arabia. The CathPCI Registry assesses the characteristics, treatments and outcomes of heart disease patients who receive diagnostic catheterization as well as percutaneous coronary intervention procedures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 27, 2018 Category: International Medicine & Public Health Source Type: news

Abiomed wins expanded Impella FDA nod for elective, urgent high-risk PCI
Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval for its Impella 2.5 and Impella CP heart pumps, now cleared for use during elective and urgent high risk percutaneous coronary intervention procedures. With the expansion, the Impella heart pump is cleared for use with patients with severe coronary artery disease, complex anatomy and a number of co-morbidities with or without depressed ejection fractions, the Danvers, Mass.-based company said. “This expanded FDA approval with moderately reduced ejection fraction validates our real-world experience using hemodynamic support in patients turned d...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Catheters Food & Drug Administration (FDA) Regulatory/Compliance Abiomed Source Type: news

Shorter time between first medical contact to PCI in heart patients linked to saving lives
(European Society of Cardiology) Heart experts are calling for immediate action following new research in the European Heart Journal that shows every minute counts for patients who suffer the most severe type of heart attack. The study shows numbers of deaths rise steadily and rapidly the longer the time between patients' first contact with a medical professional and when they are treated in hospital with percutaneous coronary intervention (PCI) to insert a balloon catheter to widen blocked arteries and restore blood flow to the heart. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 13, 2018 Category: International Medicine & Public Health Source Type: news

Cardiovascular Systems shares dip on mixed-bag Q2
Shares in Cardiovascular Systems (NSDQ:CSII) fell today after the medical device maker posted growing losses, despite having topped loss-per-share consensus on Wall Street with its second quarter earnings results. The St. Paul, Minn.-based company posted losses of $413,000, or 1¢ per hare, on sales of $52.6 million for the three months ended December 31, seeing losses grow 139.6% while sales grew by 5.2% compared with the same period last year. Losses per share were just ahead of the 4¢ consensus on Wall Street, while sells fell just short of the $53.3 million analyst’s expectations. “We are enco...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Cardiovascular Systems Inc. Source Type: news

Consumables now costlier than stents in angioplasty
Many hospitals are charging anything between Rs 32,000-42,000 and some even more, well above the cost of a stent, which has been capped at Rs 30,000. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 6, 2018 Category: Pharmaceuticals Source Type: news

Medtronic ’ s In.Pact Admiral drug-coated balloon succeeds in two-year study, critical limb ischemia analysis
Medtronic (NYSE:MDT) touted data today from a two-year study of its In.Pact Admiral drug-coated balloon in patients with peripheral artery disease in Japan, as well as the results from a critical limb ischemia subgroup analysis from its In.Pact Global trial. The company’s In.Pact SFA Japan study enrolled 100 patients and randomized them to receive either the drug-coated balloon or plain balloon angioplasty. Get the full story at our sister site, Drug Delivery Business News. The post Medtronic’s In.Pact Admiral drug-coated balloon succeeds in two-year study, critical limb ischemia analysis appeared first on...
Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Medtronic Source Type: news

Angioplasty cost falls up to 18% on stent price cap
Angioplasty cost at corporate hospital chains came down by 8-12% to ₹2.05 lakh-2.20 lakh from ₹2.10 lakh-2.20 lakh, the study showed. (Source: The Economic Times)
Source: The Economic Times - January 25, 2018 Category: Consumer Health News Source Type: news

Angioplasty cost falls up to 18 per cent on stent price cap
Angioplasty cost at corporate hospital chains came down by 8-12% to ₹2.05 lakh-2.20 lakh from ₹2.10 lakh-2.20 lakh, the study showed. (Source: The Economic Times)
Source: The Economic Times - January 25, 2018 Category: Consumer Health News Source Type: news

Doctors may be ordering too many coronary interventions
Physicians may be ordering too many percutaneous coronary intervention procedures...Read more on AuntMinnie.comRelated Reading: FFR-CT algorithm guides management of revascularization Use criteria cut unnecessary heart interventions NIH study ties soft plaque on CT to cardiac risk factors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 16, 2018 Category: Radiology Source Type: news

Localized cooling of the heart limits damage caused by a heart attack
(Eindhoven University of Technology) Researchers from Eindhoven University of Technology and the Catharina hospital in Eindhoven have succeeded in the localized cooling of the heart during a heart attack, a world first. By cooling part of the heart prior to and following angioplasty, the cardiologists believe that the damage from a heart attack can be limited. On 11 January cardiologist Luuk Otterspoor received his doctorate at Eindhoven University of Technology for this study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 12, 2018 Category: International Medicine & Public Health Source Type: news

When VA Outsources PCI, Some Patients Lose (CME/CE)
(MedPage Today) -- Survival disadvantage seen with angioplasties at non-VA centers -- but not with CABG (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 3, 2018 Category: Surgery Source Type: news

FDA Again Warns on Balloon Angioplasty for Neurologic Disorders
(MedPage Today) -- Says transvascular autonomic modulation is off-label and dangerous (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 26, 2017 Category: Primary Care Source Type: news

Better treatment, not more spending, saves heart attack patients, study finds
(Michigan Medicine - University of Michigan) A long-term look at heart attack care and spending in America in the 21st Century shows more survival, more spending, and more variation between hospitals on both scores. And while spending on rapid angioplasty appears to be paying off, a lot of the dollars spent in the six months after a heart attack aren't making a difference in the long-term death rate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2017 Category: International Medicine & Public Health Source Type: news

Bringing Robotics into the Cath Lab to Protect Physicians
Percutaneous Coronary Intervention (PCI, or angioplasty with stent) is a common procedure used to treat patients with obstructive coronary artery disease, with an estimated 600,000 procedures performed annually in the United States. PCI has a low risk of complications for patients, but that's not the case for clinicians. Patients receive a dose of radiation during a PCI procedure, which takes anywhere from 30 minutes to a few hours. Interventional cardiologists and cardiac catheterization laboratory personnel are exposed to ionizing radiation all day, every day. Protective measures, such as radiation safety caps,...
Source: MDDI - December 15, 2017 Category: Medical Devices Authors: Heather R. Johnson Tags: Medical Device Business Source Type: news

Percutaneous coronary intervention is a well-justified option also in severe coronary artery disease
(University of Eastern Finland) The treatment of left main coronary artery disease by percutaneous coronary intervention is associated with a smaller risk of severe cardiovascular events than coronary artery bypass grafting in the weeks following surgery. A meta-analysis of several trials and nearly 5,000 patients revealed no differences in mortality between the two treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news

7 medtech stories we missed this week: Dec. 8, 2017
[Image from unsplash.com]From Minimus Spine’s European distribution deal to Stimwave receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Minimus Spine inks EU distribution deal Minimus Spine announced in a Dec. 4 press release that it has signed its first European distribution deal with Italian company Moss and has completed its first commercial order. Moss has exclusive distribution rights to distribute in Italy, Germany, Switzerland and the U.K. 2. Elanix, Dermacon sign wound management development deal Elanix Biotechnologies and Dermacon...
Source: Mass Device - December 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Diagnostics Food & Drug Administration (FDA) Hospital Care Pain Management Regulatory/Compliance Cagent Vascular CSA Medical Inc. Dermacon Elanix Life Spine Inc. MedTech Minimus Spin Source Type: news

Robocath adds $2m for new neurovascular platform
Medical robotics startup Robocath said today that it added about $2 million (€1.7 million) to the more than $5 million it raised earlier this year, taking its total to $7.5 million in funding this year. Rouen, France-based Robocath, which is developing the R-One robotic platform for coronary angioplasty, is pursuing CE Mark approval in the European Union for the system. R-One is expected to hit the market in Europe and the Middle East next year, the company said. Get the full story at our sister site, The Robot Report. The post Robocath adds $2m for new neurovascular platform appeared first on MassDevic...
Source: Mass Device - December 6, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Robotics Wall Street Beat Robocath Source Type: news

FOXTROT ™ NC PTCA Balloon Catheter Gains Regulatory Approval in Argentina
(Source: Microport News Release)
Source: Microport News Release - November 24, 2017 Category: Medical Devices Source Type: news

When to Stent in Stable CAD? That Is (Still) the Question When to Stent in Stable CAD? That Is (Still) the Question
Drs Harrington, Maron, and Patel discuss the ORBITA trial, which compared coronary stenting with sham percutaneous coronary intervention for angina relief. Why did ORBITA cause so much buzz?theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2017 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Perioperative Aspirin Might Benefit Patients with Prior PCI
Perioperative aspirin seems beneficial for high-risk patients undergoing noncardiac surgery who've previously undergone percutaneous coronary intervention (PCI), according to a subanalysis from the POISE... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2017 Category: Primary Care Source Type: news

Aspirin can prevent heart attacks after noncardiac surgery in patients with prior PCI
(University of Alberta Faculty of Medicine& Dentistry) A Canadian-led study has found that perioperative aspirin can prevent heart-related complications after major noncardiac surgery in patients with previous percutaneous coronary intervention (PCI) such as an angioplasty or stent. The study found that for every 1,000 patients with PCI, giving them aspirin at the time of noncardiac surgery would prevent 59 heart attacks and cause eight major bleeding events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news

Interview with Yusuke Yoshikawa, MD
Dr. Yoshikawa discusses his study, just published in Circulation, titled "Validating Utility of DAPT Score in a Large Pooled Cohort from Three Japanese PCI Studies," and he comments on how the Japanese population differs from western patients in terms of bleeding and ischemic event rates. (posted in collaboration with TCROSS NEWS) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 10, 2017 Category: Cardiology Source Type: news

Study: PCI Appears No Better Than Sham Procedure in Patients with Stable Angina (FREE)
By Kelly Young Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Percutaneous coronary intervention (PCI) didn't improve exercise time relative to a sham procedure in patients with stable angina and severe coronary stenosis. Findings from the ORBITA study were published in the Lancet and presented at the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 3, 2017 Category: Primary Care Source Type: news

Are Artery-Opening Stents for Chest Pain a Waste of Time?
Source: HealthDay Related MedlinePlus Pages: Angina, Angioplasty, Coronary Artery Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 2, 2017 Category: Consumer Health News Source Type: news

Analysis Shows Better Health Outcomes and Cost Effectiveness for Coronary Intervention Using Abbott's Fractional Flow Reserve (FFR) Diagnostic in Patients with Stable Coronary Artery Disease
After three years, patients who underwent FFR-guided percutaneous coronary intervention (PCI) in combination with medical therapy had significantly fewer major adverse cardiac events compared to patients who received medical therapy alone (Source: Abbott.com)
Source: Abbott.com - November 2, 2017 Category: Pharmaceuticals Source Type: news

Complex CTO-PCI: The Japanese Approach
This 20 minute video shows a complex CTO case, in which an RCA obstruction, complicated by a sharp bend and tortuous anatomy, was revascularized using both the antegrade and retrograde approaches, facilitated by IVUS and biplane angiographic imaging. The operator is Dr. Etsuo Tsuchikane; the case was broadcast live during the Japanese CTO Club course in June 2017. (posted in collaboration with TCROSS NEWS) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - October 31, 2017 Category: Cardiology Source Type: news

Cordis Comes Back for Another Stent
Cordis is getting back into the coronary stent game. The company, which is now owned by Cardinal Health, landed exclusive rights to sell Medinol's coronary stent portfolio in the U.S. Milpitas, CA-based Cordis is already selling Medinol's NIRxcell cobalt-chromium bare-metal stent and, assuming FDA approves Medinol's EluNIR drug-eluting stent (DES), Cordis will distribute it as well. Medinol is based in Israel. In addition to the Medinol agreement, Cordis recently launched the Tryton Side Branch Stent and two percutaneous transluminal coronary angioplasty (PTCA) balloon catheters. The Medinol agreement, along with the ...
Source: MDDI - October 31, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Should patients with cardiogenic shock receive culprit lesion only PCI or multivessel PCI?
(Cardiovascular Research Foundation) Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2017 Category: International Medicine & Public Health Source Type: news

SCAI launches educational initiative as nation shifts to value-based healthcare
(Society for Cardiovascular Angiography and Interventions) The Society for Cardiovascular Angiography and Interventions announced today the launch of TRAnsition for VALUE, a multi-faceted educational initiative supported by Medtronic, to inform cardiologists, hospital administrators, and cath lab staff about the benefits of expanding the adoption of transradial (wrist access) percutaneous coronary intervention (PCI) in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2017 Category: International Medicine & Public Health Source Type: news

FDA clears expansion of CeloNova ’s nano-coated coronary stent trial
CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding. The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears expansion of CeloNova’s nano-coated coronary stent trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Stents Vascular CeloNova BioSciences Source Type: news

Registry data examines oral anticoagulant use in women, adverse events after PCI discharge
(American College of Cardiology) Data from the American College of Cardiology's National Cardiovascular Data Registry was the source of several published studies in recent months, including a study on predicting 30-day readmission rates for patients undergoing percutaneous coronary intervention and a study that found women were less likely to use oral anticoagulants to treat atrial fibrillation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 5, 2017 Category: International Medicine & Public Health Source Type: news

This cardiac catheter uses light and ultrasound to measure plaques
[Image from Marcu Lab/UC Davis]Researchers at the University of California at Davis combined ultrasound with light into a catheter probe to view the tiny arteries of the heart. The device uses intravascular ultrasound and fluorescence lifetime imaging (FLIm) to retrieve structural and biochemical information about plaque in the arteries to help predict heart attacks more reliably, according to the researchers. Currently, doctors use angioplasty to view blood vessels in constricted regions. A contrasting agent has to be injected to be able to view the vessels in an X-ray, but sometimes an angioplasty could miss dangerous pl...
Source: Mass Device - October 4, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Cardiovascular Catheters Diagnostics Research & Development heart disease MedTech University of California at Davis Source Type: news

Andreas Roland Gruentzig, the Man Andreas Roland Gruentzig, the Man
A fascinating profile of Andreas Gruentzig, the renowned cardiologist who first developed balloon angioplasty, and is considered the father of modern-day percutaneous coronary intervention.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news